Amylyx Pharmaceuticals specializes in providing solutions for Alzheimer’s and other diseases of the brain. Founded by Joshua Cohen and Justin Klee in 2014, Amylyx Pharmaceuticals is backed by Viking Global Investors, Perceptive Advisors, Falcon Edge Capital, Rock Springs Capital, and Morningside Venture Investments and is headquartered in Cambridge.